Cargando…

Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients

Detalles Bibliográficos
Autores principales:	Abid, Muhammad Bilal, Rubin, Micah, Ledeboer, Nathan, Szabo, Aniko, Longo, Walter, Mohan, Meera, Shah, Nirav N., Fenske, Timothy S., Abedin, Sameem, Runaas, Lyndsey, D’Souza, Anita, Chhabra, Saurabh, Dhakal, Binod, Hamadani, Mehdi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8864440/ https://www.ncbi.nlm.nih.gov/pubmed/35202585 http://dx.doi.org/10.1016/j.ccell.2022.02.010

Ejemplares similares

Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy
por: Dhakal, Binod, et al.
Publicado: (2021)

Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies
por: Mohan, Meera, et al.
Publicado: (2022)

Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy
por: Furqan, Fateeha, et al.
Publicado: (2022)

Bronchoalveolar lavage-based COVID-19 testing in patients with cancer
por: Abid, Muhammad Bilal, et al.
Publicado: (2021)

Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma
por: Hammons, Lindsay R., et al.
Publicado: (2022)

Blood and Marrow Transplantation (BMT) within Four Weeks of Sars-Cov-2 Infection Is Associated with Increased Risk of Mortality: A National COVID Cohort Collaborative Study
por: Mohan, Meera, et al.
Publicado: (2022)

Mitigation of gastrointestinal graft-versus-host disease with tocilizumab prophylaxis is accompanied by preservation of microbial diversity and attenuation of enterococcal domination
por: Chhabra, Saurabh, et al.
Publicado: (2022)

Prognostic impact of immunophenotypic aberrancies of blasts in lower risk myelodysplastic syndrome
por: Corrao, Kristen, et al.
Publicado: (2022)

P1082: RESULTS FROM A PHASE 1/2 STUDY OF TANDEM, BISPECIFIC ANTI-CD20/ANTI-CD19 (LV20.19) CAR T-CELLS FOR MANTLE CELL LYMPHOMA
por: Shah, Nirav N, et al.
Publicado: (2023)

Experimental Pharmaceuticals for Steroid-Refractory Acute Graft-versus-Host Disease
por: Abedin, Sameem, et al.
Publicado: (2020)

Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol
por: Johnson, Alexander K., et al.
Publicado: (2022)

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
por: Dhakal, Binod, et al.
Publicado: (2019)

Efficacy of a Third Sars-Cov-2 Vaccine Dose in Allogeneic Hemopoietic Cell Recipients: a Systematic Review and Meta-Analysis
por: Rubin, Micah, et al.
Publicado: (2023)

Adjuvant doxycycline to enhance anti-amyloid effects: Results from the dual phase 2 trial
por: D'Souza, Anita, et al.
Publicado: (2020)

Prevalence and Significance of Sarcopenia in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
por: Williams, Alexis, et al.
Publicado: (2020)

Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis
por: D'Souza, Anita, et al.
Publicado: (2017)

Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma
por: Mohan, Meera, et al.
Publicado: (2022)

CAR T-cell therapy for secondary CNS DLBCL
por: Ahmed, Gulrayz, et al.
Publicado: (2021)

Gut microbiome and CAR-T therapy
por: Abid, Muhammad Bilal, et al.
Publicado: (2019)

Letter to the Editor Regarding “Diagnostic Considerations for COVID-19 in Recipients of Allogeneic Hematopoietic Cell Transplantation”
por: Chhabra, Saurabh, et al.
Publicado: (2020)

Repurposing existing medications as cancer therapy: design and feasibility of a randomized pilot investigating propranolol administration in patients receiving hematopoietic cell transplantation
por: Knight, Jennifer M., et al.
Publicado: (2018)

BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
por: Wu, James F., et al.
Publicado: (2023)

Early immunomodulators with CAR T-cell immunotherapy in the COVID-19 era
por: Abid, Muhammad Bilal
Publicado: (2022)

Laboratory Mice – A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma
por: Pisano, Michael, et al.
Publicado: (2021)

CAR-T cells and BiTEs in solid tumors: challenges and perspectives
por: Edeline, Julien, et al.
Publicado: (2021)

Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-versus-host disease: low incidence of lower gastrointestinal tract disease
por: Drobyski, William R., et al.
Publicado: (2018)

Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes
por: Knight, Jennifer M., et al.
Publicado: (2022)

BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects
por: Abedin, Sameem M, et al.
Publicado: (2016)

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
por: Iqbal, Madiha, et al.
Publicado: (2021)

Bite-on-bite technique for removal of a gastric subepithelial lipoma
por: Ehrlich, Dean, et al.
Publicado: (2019)

State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses
por: Meir, Juliet, et al.
Publicado: (2021)

Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients – targeting the target antigen
por: Uyemura, Bradley S., et al.
Publicado: (2022)

Harnessing T Cells to Target Pediatric Acute Myeloid Leukemia: CARs, BiTEs, and Beyond
por: Epperly, Rebecca, et al.
Publicado: (2020)

Localized Lymph Node Light Chain Amyloidosis
por: Dhakal, Binod, et al.
Publicado: (2015)

1192. Identification of a Novel Enterobacter cloacae Isolate Producing an IMP-13 Metallo-β-Lactamase
por: Abid, Muhammad Bilal, et al.
Publicado: (2018)

Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
por: Kegyes, David, et al.
Publicado: (2022)

BiTE‐Secreting CAR‐γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors
por: Huang, Shi‐Wei, et al.
Publicado: (2023)

Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy
por: Knight, Jennifer M., et al.
Publicado: (2022)

Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study
por: Dong, Jing, et al.
Publicado: (2022)

Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma
por: Li, Gaowei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7b88m3ber6ctal5cs5bf3umc56